Global Meningococcal Initiative: guidelines for diagnosis and confirmation of invasive meningococcal disease

Epidemiology and Infection

Volumn 144, Issue 14, 2016, Pages 3052-3057

  Vazquez J A ^a   Taha, M K ^b   Findlow, J ^c   Gupta, S ^d   Borrow, R ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUT PASTEUR   (France)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d National Centre for Disease Control   (India)

Author keywords

Diagnosis; GMI; Meningitis; Meningococcal disease

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIGEN SEQUENCE TYPING; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE SURVEILLANCE; DNA SEQUENCE; FETA GENE; GOOD LABORATORY PRACTICE; INFECTION PREVENTION; LABORATORY TEST; MENINGOCOCCOSIS; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; NEISSERIA MENINGITIDIS; POLYMERASE CHAIN REACTION; PORA GENE; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; REVIEW; SEROTYPING; SPECIMEN HANDLING; VACCINATION; WHOLE GENOME SEQUENCING; HUMAN; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; PUBLIC HEALTH;

GUIDELINES AS TOPIC; HUMANS; MENINGOCOCCAL INFECTIONS; PUBLIC HEALTH;

EID: 85027950968     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268816001308     Document Type: Review

References (38)

1. Harrison LH, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011; 29: 3363- 3371.
2. John TJ, et al. An overview of meningococcal disease in India: knowledge gaps and potential solutions. Vaccine 2013; 31: 2731-2737.
3. Sáfadi MA, et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Expert Review of Vaccines 2013; 12: 903-915.
4. Borrow R, et al. Safe laboratory handling of Neisseria meningitidis. Journal of Infection 2014; 68: 305-312.
5. Shrestha NK. Infectious Disease Emergencies. Cleveland Clinic Center for Continuing Education (http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infectious-disease/infectious-diseaseemergencies/). Accessed 21 September 2015.
6. Centers for Disease Control and Prevention. Meningococcal disease (Neisseria meningitidis). 2015 case definition. CDC website (http://wwwn.cdc.gov/nndss/conditions/meningococcal-disease/case-definition/2015). Accessed 10 June 2015.
7. European Centre for Disease Prevention and Control. Meningococcal disease, invasive (Neisseria meningitidis). ECDC website (http://www.ecdc.europa.eu/en/activities/surveillance/EU-IBD/Pages/Case-definition.aspx). Accessed 10 June 2015.
8. Department of Health, Australian Government. Meningococcal disease (invasive) surveillance case definition - V1.4. DOH website (http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveilnndss-casedefs-cd-mening.htm). Accessed 10 June 2015.
9. Olcen P, Fredlund H. Isolation, culture, and identification of meningococci from clinical specimens. Methods in Molecular Medicine 2001; 67: 9-21.
10. Centers for Disease Control and Prevention. Laboratory methods for diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. CDC website (http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/menigitis-manual.pdf). Accessed 10 June 2015.
11. Sobanski MA, Barnes RA, Coakley WT. Detection of meningococcal antigen by latex agglutination. Methods in Molecular Medicine 2001; 67: 41-59.
12. Cunningham SA, Mainella JM, Patel R. Misidentification of Neisseria polysaccharea as Neisseria meningitidis with the use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. Journal of Clinical Microbiology 2014; 52: 2270-2271.
13. Health Protection Agency Meningococcus and Haemophilus Forum. Guidance for public health management of meningococcal disease in the UK. HPA website (https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/322008/Guidance-for-management-of-meningococcal-disease-pdf.pdf). Accessed 21 September 2015.
14. Cartwright KA, Stuart JM, Robinson PM. Meningococcal carriage in close contacts of cases. Epidemiology and Infection 1991; 106: 133-141.
15. Collard JM, et al. A five-year field assessment of rapid diagnostic tests for meningococcal meningitis in Niger by using the combination of conventional and real-time PCR assays as a gold standard. Transactions of the Royal Society of Tropical Medicine and Hygiene 2014; 108: 6-12.
16. Agnememel A, et al. Development and evaluation of a dipstick diagnostic test for Neisseria meningitides serogroup X. Journal of Clinical Microbiology 2015; 53: 449-454.
17. Chanteau S, et al. New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y. PLoS Medicine 2006; 3: e337.
18. Kaczmarski EB, et al. Creating a national service for the diagnosis of meningococcal disease by polymerase chain reaction. Communicable Diseases Public Health 1998; 1: 54-56.
19. Bryant PA, et al. Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children. Journal of Clinical Microbiology 2004; 42: 2919-2925.
20. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, 2011. ECDC website (http://ecdc.europa.eu/en/publications/Publications/invasive-bacterial-diseases-surveillance-2011.pdf). Accessed 10 June 2015.
21. Bennett DE, Cafferkey MT. Consecutive use of two multiplex PCR-based assays for simultaneous identification and determination of capsular status of nine common Neisseria meningitidis serogroups associated with invasive disease. Journal of Clinical Microbiology 2006; 44: 1127-1131.
22. Dolan Thomas J, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS ONE 2011; 6: e19361.
23. Hedberg ST, et al. Real-time PCR detection of five prevalent bacteria causing acute meningitis. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2009; 117: 856-860.
24. Mölling P, et al. Direct and rapid identification and genogrouping of meningococci and porA amplification by LightCycler PCR. Journal of Clinical Microbiology 2002; 40: 4531-4535.
25. Taha MK, et al. Interlaboratory comparison of PCRbased identification and genogrouping of Neisseria meningitidis. Journal of Clinical Microbiology 2005; 43: 144-149.
26. Bratcher HB, et al. A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes. BMC Genomics 2014; 15: 1138.
27. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiology Reviews 2007; 31: 15-26.
28. Fox AJ, Taha MK, Vogel U. Standardized nonculture techniques recommended for European reference laboratories. FEMS Microbiology Reviews 2007; 31: 84-88.
29. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiology Reviews 2007; 31: 89-96.
30. Lucidarme J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clinical and Vaccine Immunology 2010; 17: 919-929.
31. Jolley KA, Maiden MC. Automated extraction of typing information for bacterial pathogens from whole genome sequence data: Neisseria meningitidis as an exemplar. Eurosurveillance 2013; 18: 20379.
32. Vogel U, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: A qualitative and quantitative assessment. Lancet Infectious Diseases 2013; 13: 416-425.
33. Donnelly J, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 19490-19495.
34. Kelly A, et al. Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 2013; 121: 56-63.
35. Hong E, et al. Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin. Antimicrobial Agents and Chemotherapy 2013; 57: 1961-1964.
36. Taha MK, et al. Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis. Antimicrobial Agents and Chemotherapy 2007; 51: 2784-2792.
37. Taha MK, et al. Multicenter study for defining the breakpoint for rifampin resistance in Neisseria meningitidis by rpoB sequencing. Antimicrobial Agents and Chemotherapy 2010; 54: 3651-3658.
38. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Human Vaccines 2011; 7: 170-182.